1062169-58-7

Basic information

• Product Name: methyl 4-[6-(4-aminophenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate
• Synonyms: methyl 4-[6-(4-aminophenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate
• CAS NO: 1062169-58-7
• Molecular Weight: 437.501
• Mol File: 1062169-58-7.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl 4-[6-(4-aminophenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-[6-(4-aminophenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate(1062169-58-7)
• EPA Substance Registry System: methyl 4-[6-(4-aminophenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate(1062169-58-7)

Safety Data

• Hazardous Substances Data: 1062169-58-7(Hazardous Substances Data)

Upstream product

• 1062173-85-6 4-(6-chloro-4-morpholin-4-ylpyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylic acid methyl ester 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1062171-60-1 methyl 4-(6-(4-(3-(4-fluorophenyl)ureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062173-19-6 methyl 4-(4-morpholino-6-(4-(phenoxycarbonylamino)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062169-48-5 methyl 4-(6-{4-[(anilinocarbonyl)amino]phenyl}-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062172-39-7 methyl 4-[6-(4-([(2-hydroxyethoxy)carbonyl]amino)phenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate 
• 1062169-41-8 methyl 4-(6-(4-[(ethylcarbamoyl)amino]phenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062169-42-9 methyl 4-[6-(4-([(2-fluoroethyl)carbamoyl]amino)phenyl)-4-morpholin-4-yl-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carboxylate 
• 1062172-60-4 methyl 4-(6-(4-(3-(4-(hydroxymethyl)phenyl)ureido)phenyl)-4-morpholino-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062169-56-5 WYE-354 
• 1062169-55-4 methyl 4-(4-morpholin-4-yl-6-(4-[(pyridin-4-ylcarbamoyl)amino]phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 
• 1062169-53-2 methyl 4-(4-morpholin-4-yl-6-(4-[(pyridin-3-ylcarbamoyl)amino]phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

Discovery of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 6-aryl substituent

Design and synthesis of a series of 4-morpholino-6-aryl-1H-pyrazolo[3,4-d] pyrimidines as potent and selective inhibitors of the mammalian target of rapamycin (mTOR) are described. Optimization of the 6-aryl substituent led to the discovery of inhibitors carrying 6-ureidophenyl groups, the first reported active site inhibitors of mTOR with subnanomolar inhibitory concentrations. The data presented in this paper show that 6-arylureidophenyl substituents led to potent mixed inhibitors of mTOR and phosphatidylinositol 3-kinase α (PI3K-α), whereas 6-alkylureidophenyl appendages gave highly selective mTOR inhibitors. Combination of 6-alkylureidophenyl groups with 1-carbamoylpiperidine substitution resulted in compounds with subnanomolar IC50 against mTOR and greater than 1000-fold selectivity over PI3K-α. In addition, structure based drug design resulted in the preparation of several 6-arylureidophenyl-1H-pyrazolo[3,4-d]pyrimidines, substituted in the 4-position of the arylureido moiety with water solubilizing groups. These compounds combined potent mTOR inhibition (IC50501 nM). 2009 American Chemical Society.

PYRAZOLOPYRIMIDINE ANALOGS AND THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS

The present invention relates to Pyrazolopyrimidine Analogs, methods of making Pyrazolopyrimidine Analogs, compositions comprising a Pyrazolopyrimidine Analog, and methods for treating mTOR-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog. The invention also relates to treating PI3K-related disorders comprising administering to a subject in need thereof an effective amount of a Pyrazolopyrimidine Analog.